Physician profile
Hardeep M Singh
NPI 1275544074
$14,113.53
in general payments reported to CMS, 2019-2025
50 companies · $2,795 in 2025
The $2,795 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $1,188 · 2021: $1,795 · 2022: $2,167 · 2023: $2,229 · 2024: $2,524 · 2025: $2,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,548.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,978.87 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,912.86 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,075.35 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $807.66 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $664.05 | 2019-2025 | Exalt Model D, Axios, X-Tack Endoscopic Helix Tacking System |
| Pfizer INC. | $597.13 | 2019-2025 | |
| Janssen Biotech, INC. | $504.81 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Ardelyx, INC. | $397.64 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $364.19 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $325.21 | 2025 | Rezdiffra |
| Genzyme Corporation | $321.74 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $254.56 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $214.12 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $198.55 | 2019-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $187.76 | 2019-2021 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $178.12 | 2019 | |
| Steris Corporation | $168.94 | 2024 | |
| Nestle Healthcare Nutrition INC. | $155.73 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $152.96 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $144.96 | 2023-2025 | Voquezna |
| Braintree Laboratories, INC. | $122.00 | 2020-2025 | Suflave, Sutab |
| Redhill Biopharma INC. | $120.10 | 2020-2023 | Talicia |
| Merck Sharp & Dohme LLC | $118.24 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $113.28 | 2022-2025 | Dupixent |
| Amgen INC. | $90.44 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $87.50 | 2022 | |
| Vivus LLC | $87.07 | 2024-2025 | Qsymia, Pancreaze |
| Conmed Corporation | $82.65 | 2019 | |
| Celltrion USA INC. | $74.62 | 2024-2025 | Vegzelma, Zymfentra |
| Shionogi INC | $69.89 | 2019 | |
| Shire North American Group INC | $63.31 | 2019 | |
| Allergan, INC. | $59.69 | 2019-2020 | |
| Alfasigma USA, INC. | $50.94 | 2020 | |
| Lilly USA, LLC | $49.17 | 2024-2025 | Omvoh |
| Fresenius Kabi USA, LLC | $29.98 | 2023 | |
| Biocon Biologics INC | $26.24 | 2025 | Hulio |
| Intra-Sana Laboratories | $26.06 | 2021 | |
| Sandoz INC. | $25.87 | 2023 | Hyrimoz |
| Exact Sciences Corporation | $24.23 | 2024 | Cologuard Collection Kit |
| Abiomed | $23.33 | 2024 | Impella |
| Amag Pharmaceuticals, INC. | $22.07 | 2019 | |
| Ucb, INC. | $20.31 | 2020 | |
| Shield Therapeutics INC | $20.29 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2024 | Cyltezo |
| Capsovision, INC. | $19.25 | 2023 | Capsocam Plus |
| Daiichi Sankyo INC. | $18.40 | 2019 | |
| Evoke Pharma, INC. | $16.07 | 2023 | Gimoti |
| Pinnacle Biologics, INC | $11.57 | 2021 | |
| Dynavax Technologies Corporation | $10.24 | 2019 | |
| Ambu INC. | $5.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.